[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100653000":3},{"organization":4,"outcomesModule":7,"designInfo":49,"detailedDescription":55,"studyPopulation":48,"armGroups":56,"interventions":63,"overallOfficials":48,"centralContacts":48,"locations":48,"responsibleParty":69,"collaborators":48,"id":71,"slug":72,"hasResults":73,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":79,"sex":80,"minAge":81,"maxAge":48,"enrollmentInfo":82,"targetDuration":48,"studyType":85,"phases":86,"briefSummary":87,"conditions":88,"keywords":90,"overallStatus":92,"whyStopped":48,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":48},{"fullName":5,"class":6},"The Royal Wolverhampton Hospitals NHS Trust","OTHER_GOV",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":48},[9],{"measure":10,"description":11,"timeFrame":12},"Agreement between Tasso+ capillary serum and venous serum 25(OH)D","Continuous 25(OH)D₂ and 25(OH)D₃ concentrations (nmol\u002FL)","From Study start date for up to 12 months",[14,17,20,22,24,26,28,31,33,36,38,40,43,46],{"measure":15,"description":16,"timeFrame":12},"User acceptability","Pain, on a scale from 1-5\n\n1= no pain. 5= worse pain",{"measure":15,"description":18,"timeFrame":19},"Ease of Use: how easy or difficult each method was to complete\n\n1= Very difficult, 5=Very easy\n\nDried Bloodspot Venepuncture Tasso+","From study start date to 12 months",{"measure":15,"description":21,"timeFrame":12},"Clarity of Instructions: how clear were the instructions you were given?\n\n1= Not clear at all, 5=Extremely clear\n\nDried Bloodspot Venepuncture Tasso+",{"measure":15,"description":23,"timeFrame":12},"Safety: How safe did each method feel to you ?\n\n1= Very unsafe, 5=Very safe\n\nDried Bloodspot Venepuncture Tasso+",{"measure":15,"description":25,"timeFrame":12},"Your Preference: please rank the three collection methods\n\n1= your favourite, 3=least preferred\n\nDried Bloodspot Venepuncture Tasso+",{"measure":15,"description":27,"timeFrame":12},"Willingness to self-collect: how willing would you be to collect your own sample using each method in the future?\n\n1= Very willing, 5=Very willing\n\nDried Bloodspot Venepuncture Tasso+",{"measure":29,"description":30,"timeFrame":12},"Sample quality","Volume adequacy- minimum blood vol 200uL",{"measure":29,"description":32,"timeFrame":12},"Pre analytical failure- % samples unacceptable for analysis due to inadequate volume or poor quality blood spot",{"measure":34,"description":35,"timeFrame":12},"Laboratory workflow efficiency","Hands on time (hrs\u002Fmins)",{"measure":34,"description":37,"timeFrame":12},"Batch failures based on LCMSMS batch acceptance criteria- QC with +\u002F- 2sd of mean, cal curve R value \\> 0.95",{"measure":34,"description":39,"timeFrame":12},"Repeat samples (%)",{"measure":41,"description":42,"timeFrame":12},"Turnaround time (TAT)","Time from sample request to result authorisation",{"measure":44,"description":45,"timeFrame":12},"Clinical classification agreement","Numerical agreement (statistically quantified by Passing and Bablok analysis)",{"measure":44,"description":47,"timeFrame":12},"Vitamin D status category agreement (deficient \u002F insufficient \u002F replete) quantified statistically using Cohen's kappa analysis",null,{"allocation":50,"interventionModel":51,"interventionModelDescription":48,"primaryPurpose":52,"observationalModel":48,"timePerspective":48,"maskingInfo":53},"NA","SINGLE_GROUP","SUPPORTIVE_CARE",{"masking":54,"maskingDescription":48,"whoMasked":48},"NONE","This study will evaluate the performance and acceptability of different sampling methods for measuring vitamin D, specifically 25-hydroxyvitamin D₂ and 25-hydroxyvitamin D₃. It will compare results obtained from the routine self-collected dried blood spot (DBS) cards currently in use in our laboratory, with paired capillary and venous serum samples. This compares the collection using three approaches: finger-prick DBS, venepuncture, and the CE-marked Tasso+ upper-arm self-sampling device. The study aims to assess both quantitative agreement between sample types and user acceptability of each collection method.",[57],{"label":58,"type":59,"description":60,"interventionNames":61},"Vitamin D sampling","EXPERIMENTAL","Staff members having Vit D sampling using blood spot, venous samples, and sample collected using the device",[62],"Device: Vit D Tasso+",[64],{"type":65,"name":66,"description":67,"armGroupLabels":68,"otherNames":48},"DEVICE","Vit D Tasso+","Blood collected using Tasso device",[58],{"type":70,"investigatorFullName":48,"investigatorTitle":48,"investigatorAffiliation":48,"oldNameTitle":48,"oldOrganization":48},"SPONSOR","100653000","comparing-vitamin-d-results-and-acceptability-of-sampling-obtained-from-dried-blood-spot-tasso-capillary-sampling-and-venous-blood-100653000",false,"NCT07782528","Comparing Vitamin D Results and Acceptability of Sampling Obtained From Dried Blood Spot, Tasso+ Capillary Sampling, and Venous Blood.","Evaluation of a Capillary Self-sampling Device for Vitamin D Testing","VitD TASSO","Inclusion Criteria:\n\n* Adults aged 18 years or older.\n* Current healthcare staff or staff volunteers.\n* Already consented to use the routine dried blood spot (DBS) vitamin D service.\n* Able and willing to provide all three sample types- routine DBS finger-prick sample, a Tasso+ upper-arm self-collected capillary sample, and a venous blood sample taken by a trained Trust phlebotomist.\n* Able to give informed consent.\n* Able to complete a short questionnaire in English.\n\nExclusion Criteria:\n\n* • Participants will not be able to take part if any of the following apply:\n\n  * Under 18 years of age\n  * Not a member of staff or staff volunteer\n  * Known difficulty with blood sampling, such as a history of fainting, severe needle phobia, or conditions that make venepuncture unsafe.\n  * Skin conditions or injuries on the upper arm that would prevent safe use of the Tasso+ device.\n  * Bleeding disorders or current use of anticoagulant medication that would make capillary or venous sampling unsafe.\n  * Inability to give informed consent, including difficulty understanding the study information.\n  * Inability to complete the short questionnaire in English, as this is needed to assess user experience.",true,"ALL","18 Years",{"count":83,"type":84},35,"ESTIMATED","INTERVENTIONAL",[50],"This study will evaluate the performance and acceptability of different sampling methods for measuring vitamin D, specifically 25-hydroxyvitamin D₂ and 25-hydroxyvitamin D₃.",[89],"Vitamin D",[91],"Vitamin D Tasso","NOT_YET_RECRUITING","2026-08-19",{"date":95,"type":96},"2026-08-24","ACTUAL",{"date":98,"type":84},"2027-01",{"date":100,"type":84},"2027-12",{"name":5,"class":6}]